PGLs and PCCs are associated with several hereditary cancer and tumor predisposition syndromes, including multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), von Hippel–Lindau syndrome (VHL), neurofibromatosis type 1 (NF1), hereditary leiomyomatosis and renal cell cancer (HLRCC), and hereditary paraganglioma–pheochromocytoma syndrome (HPPS). This evidence concerns the gene NF1 and hereditary leiomyomatosis and renal cell cancer.